Private Asset Management Inc. cut its stake in Johnson & Johnson (NYSE:JNJ) by 8.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 112,586 shares of the company’s stock after selling 10,980 shares during the period. Johnson & Johnson comprises approximately 2.5% of Private Asset Management Inc.’s portfolio, making the stock its 10th largest position. Private Asset Management Inc.’s holdings in Johnson & Johnson were worth $15,731,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Abner Herrman & Brock LLC lifted its position in Johnson & Johnson by 8.6% in the fourth quarter. Abner Herrman & Brock LLC now owns 30,882 shares of the company’s stock valued at $4,315,000 after acquiring an additional 2,445 shares during the last quarter. Hefty Wealth Partners lifted its position in Johnson & Johnson by 959.3% in the fourth quarter. Hefty Wealth Partners now owns 6,970 shares of the company’s stock valued at $974,000 after acquiring an additional 6,312 shares during the last quarter. Washington Trust Bank lifted its position in Johnson & Johnson by 6.4% in the fourth quarter. Washington Trust Bank now owns 30,671 shares of the company’s stock valued at $4,285,000 after acquiring an additional 1,845 shares during the last quarter. Atlantic Trust Group LLC lifted its position in Johnson & Johnson by 23.4% in the third quarter. Atlantic Trust Group LLC now owns 2,060,040 shares of the company’s stock valued at $267,827,000 after acquiring an additional 391,068 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its position in Johnson & Johnson by 3.3% in the third quarter. Parametric Portfolio Associates LLC now owns 8,026,652 shares of the company’s stock valued at $1,043,545,000 after acquiring an additional 253,568 shares during the last quarter. 67.21% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have commented on JNJ shares. BTIG Research restated a “sell” rating and issued a $110.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Vetr lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $147.40 price objective on the stock. in a research note on Monday, January 8th. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. BMO Capital Markets lifted their price objective on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th. Finally, Wells Fargo restated an “outperform” rating and issued a $160.00 price objective (up from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $146.26.
In other news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.19% of the company’s stock.
Johnson & Johnson (JNJ) opened at $130.24 on Tuesday. Johnson & Johnson has a one year low of $120.95 and a one year high of $148.32. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.51. The stock has a market cap of $358,650.34, a PE ratio of 18.31, a PEG ratio of 2.13 and a beta of 0.77.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The business had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same period in the previous year, the business posted $1.58 earnings per share. The business’s revenue was up 11.5% compared to the same quarter last year. research analysts predict that Johnson & Johnson will post 8.11 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th were paid a dividend of $0.84 per share. The ex-dividend date was Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.58%. Johnson & Johnson’s dividend payout ratio (DPR) is 861.54%.
COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/20/johnson-johnson-jnj-is-private-asset-management-inc-s-10th-largest-position.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.